LEXAGENE HOLDINGS COM NPV (OTCMKTS:LXXGF) Is On The Move

LEXAGENE HOLDINGS COM NPV (OTCMKTS:LXXGF) is uniquely positioned to capitalize on the multibillion-dollar, underserved pathogen testing market.We’re going to talk about this company, highlighting its revenue opportunities and the steps it has taken that we find exciting.More details on this coming shortly. First take a look at the price action below. LXXGF Daily ChartHere’s a brief recap of what the chart above is saying. Investors in LXXGF have seen their investment in the stock return more than 51% in gains since the beginning of the year. And it just a couple of days between October 10 and October 12, the stock returned more than 45% to investors. LXXGF ended October 12 at $1.15 a share, up 9.6% on the day.Business model and industryLet’s briefly review the business model of LXXGF.LXXGF is a biotechnology company focused on developing instrumentation that performs automated, rapid pathogen detection. Its instruments are designed to be easy to use, thus can be used by facility personnel with little or no specialized molecular biology training.The company targets its pathogen detection technology to food safety, water quality monitoring, veterinary diagnostics and aquaculture pathogen surveillance markets.An exciting revenue opportunityAccording to research firm MarketsandMarkets, the global food pathogen testing market will be worth $10.8 billion by 2020, implying a significant average annual growth of 7.8% between 2015 and 2020. Food pathogen testing is done to supervise the quality and potentially avert incidents of foodborne illnesses.The rapid expansion of the food pathogen testing market is driven by factors such as the necessity to ensure food health and safety and increased consumer awareness of food safety. Increasing demand for processed meat and dairy products along with increasing vegetables consumption are also fueling growth of the food pathogen testing market.Growth of food pathogen testing market is also backed by stringent safety standards by organizations such as United Nations’ FAO (Food and Agriculture Organization), FDA (US Food and Drug Administration) and the EU (the European Union).Water quality monitoring market also presents an exciting revenue opportunity. According to MarketsandMarkets, global water quality monitoring market will be worth $4.69 billion by 2025, up from $2.95 billion in 2015. As such, water quality monitoring is seen expanding at an annual average of 4.54% between 2016 and 2025.Growth catalysts in this market include government policies designed to curb pollution. Such policies are encouraging uptake of pollution monitoring instruments.According to MarketsandMarkets still, the global veterinary diagnostics market will grow to $3.62 billion by 2022, implying an average annual expansion rate of 9.3%. Growth catalysts in this market include growing animal population, rising pet adoption and growing demand for animal-derived foods.LXXGF is on track to become the first provider of instrumentation capable of detecting any pathogen of interest, and this would see it enter the global pathogen testing market that will be worth more than $17.8 billion in the next couple of years. The company’s LX6 Alpha prototype is expected to be complete by next month.Recent significant developmentsWe’ve been tracking announcements from LXXGF, and we recently took note of a few developments that are worth pointing out to our readers.On September 14, LXXGF released the outcome from its Annual General and Special Meeting of Shareholders that was held on September 12, 2017. Among the proposals that were put forward at the meeting was the election of board members to sit on the company’s board of directors.LXXGF said that shareholders endorsed its director nominees. They elected directors are Dr. Jack Regan, Daryl Rebeck, Tom Slezak, Dr. Eric Olsen and Dr. Manohar Furtado.We’ll talk a little more about Furtado.Furtado is an immensely resourceful and professionally connected executive whose election to the board of LXXGF we view as potentially transformative. He has worked in the life sciences industry for more than 30 years and has overseen numerous successful projects and programs. He has experience in discovery research, clinical diagnostic testing, product development, M&A (merger and acquisition activity), fundraising and strategy.Furtado is currently serving as president and founder of Biology for Global Good LLC and as Chief Scientific Officer and Chief Regulatory Officer at Apton Biosystems. He was vice president of R&D (research and development) and Applied Biosystems, where he led medicine platforms that generated more than $500 million in revenues.Regarding the naming of Furtado to the board, Dr. Jack Regan, the CEO of LXXGF, commented that:

“Dr. Furtado is joining LexaGene’s Board of Directors at a pivotal moment for the company, as we are continuing to push forward with the building and testing of our first-of-its-kind prototype for rapid pathogen detection. As such, Dr. Furtado’s in-depth knowledge and experience across the human health and safety landscapes will serve us well as we come closer to completing our instrument and changing the future of pathogen detection as we know it today.”

SourceConclusionWith the first of its kind pathogen detection technology, we view LXXGF as uniquely positioned in the growing but underserved $17.8 billion pathogen testing market.We will be updating our subscribers as soon as we know more. For the latest updates on LXXGF, sign up below!Disclosure: We have no position in LXXGF and have not been compensated for this article.